Yong‐Chen Lu
Assistant Professor (Tenure Track)
University of Arkansas for Medical Sciences
faculty
Pathology, College of Medicine
Research Areas
Is this your profile? Verify and claim your profile
Biography and Research Information
OverviewAI-generated summary
Yong‐Chen Lu investigates the molecular mechanisms underlying cancer immunotherapy, with a particular focus on T-cell biology and the identification of neoantigens. His research group employs high-throughput single-cell sequencing technologies to directly identify neoantigen-specific T-cell receptors (TCRs) from tumor specimens. This work aims to advance adoptive cellular therapies by characterizing antitumor neoantigen-reactive T cells from metastatic human cancers and developing strategies for engineered T cells targeting common neoantigens in solid tumors.
Lu's recent publications also explore the role of liquid biopsies in hepatocellular carcinoma for immunotherapy and the application of single-cell TCR and transcriptome analysis as tools for studying T-cell responses in cancer. He has also investigated the role of TREM-2 in mediating dendritic cell function to ameliorate chronic kidney diseases. His scholarship metrics include an h-index of 28 and over 12,000 citations across 90 publications, designating him as a highly cited researcher.
He collaborates with researchers at the University of Arkansas for Medical Sciences, including Charles M. Quick, Mayumi Nakagawa, Hannah Coleman, and Takeo Shibata, with whom he has co-authored multiple publications.
Metrics
- h-index: 28
- Publications: 90
- Citations: 12,171
Selected Publications
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026) DOI
- Isolation of mitochondrial mutation-specific T cell receptors (2025) DOI
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025) DOI
- Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation (2025) DOI
- 376 Inhibition of GSK3β-mediated 53BP1 T334 phosphorylation in T cells enhances infiltration and cytotoxicity against head and neck squamous cell carcinoma (2024) DOI
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3. (2024) DOI
- Deciphering CD4<sup>+</sup> T cell‐mediated responses against cancer (2024) DOI
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023) DOI
- 867 Epigenomic and gene expression defects in sezary syndrome (2022) DOI
- Oral Shedding of an Oncogenic Virus Alters the Oral Microbiome in HIV+ Patients (2022) DOI
- Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy (2021) DOI
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed (2021) DOI
- Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy (2021) DOI
- Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing (2021) DOI
- Single-Cell TCR and Transcriptome Analysis: An Indispensable Tool for Studying T-Cell Biology and Cancer Immunotherapy (2021) DOI
Grants & Funding
- Developing T cell-based immunotherapy targeting breast cancer antigen FBXO39 ABCRP Principal Investigator
- Developing CD4 T cell-based immunotherapy for breast cancer ABCRP Principal Investigator
- Defining tumor infiltrating B cells and their role in the modulation of TIL immunotherapy The Mark Foundation for Cancer Research - Pass Through: H Lee Moffitt Cancer Center & Research Institute Co-Investigator
- A pilot study of developing T cell-based cancer immunotherapies for African American and Hispanic populations TRI Principal Investigator
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics